GLI1-IN-1 is a small molecule inhibitor that specifically targets the GLI family of transcription factors, particularly GLI1, which plays a crucial role in the Hedgehog signaling pathway. This pathway is significant in various biological processes, including cell differentiation, proliferation, and tissue patterning. Dysregulation of GLI1 has been implicated in several cancers, making it a potential therapeutic target. GLI1-IN-1 is characterized by its ability to disrupt the interaction between GLI1 and its co-activators, thereby inhibiting GLI1-mediated transcriptional activity. The compound is typically evaluated for its efficacy in preclinical studies, focusing on its potential to reduce tumor growth in GLI1-dependent malignancies. Additionally, its pharmacokinetic properties, such as solubility, stability, and bioavailability, are essential for determining its suitability for further development as a therapeutic agent. Overall, GLI1-IN-1 represents a promising avenue for targeted cancer therapy, particularly in tumors where the Hedgehog signaling pathway is aberrantly activated.

GLI1-IN-1

2923907-92-8: GLI1-IN-1 is a small molecule inhibitor that specifically targets the GLI family of transcription factors, particularly GLI1, which plays a crucial role in the Hedgehog signaling pathway. This pathway is significant in various biological processes, including cell differentiation, proliferation, and tissue patterning. Dysregulation of GLI1 has been implicated in several cancers, making it a potential therapeutic target. GLI1-IN-1 is characterized by its ability to disrupt the interaction between GLI1 and its co-activators, thereby inhibiting GLI1-mediated transcriptional activity. The compound is typically evaluated for its efficacy in preclinical studies, focusing on its potential to reduce tumor growth in GLI1-dependent malignancies. Additionally, its pharmacokinetic properties, such as solubility, stability, and bioavailability, are essential for determining its suitability for further development as a therapeutic agent. Overall, GLI1-IN-1 represents a promising avenue for targeted cancer therapy, particularly in tumors where the Hedgehog signaling pathway is aberrantly activated.

<p>GLI1-IN-1 (CBC-1), a GLI-1 inhibitor, exhibits superior water solubility and anticancer properties. It effectively induces apoptosis and inhibits colorectal cancer growth by targeting the Hedgehog (HH) pathway (IC 50 = 1.3 μM) [1].</p>

CAS 2923907-92-8

GLI1-IN-1

GLI1-IN-1

Ref: TM-T86501